2 weeks Ago By ABMN Staff
Xponance Inc. boosted its stake in shares of Glaukos Co. ( NYSE:GKOS – Free Report ) by 13.
3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,633 shares of the medical instruments supplier’s stock after purchasing an additional 426 shares during the quarter. Xponance Inc.
’s holdings in Glaukos were worth $545,000 at the end of the most recent quarter. A number of other hedge funds have also recently bought and sold shares of the stock. Wellington Management Group LLP increased its position in shares of Glaukos by 294.
5% during the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. William Blair Investment Management LLC acquired a new position in shares of Glaukos in the 4th quarter worth approximately $121,390,000.
Charles Schwab Investment Management Inc. increased its holdings in Glaukos by 47.7% during the 3rd quarter.
Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after purchasing an additional 207,338 shares in the last quarter. Raymond James Financial Inc.
bought a new position in shares of Glaukos in the fourth quarter valued at about $16,910,000. Finally, State Street Corp raised its position in shares of Glaukos by 5.3% during the third quarter.
State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after acquiring an additional 98,109 shares during the last quarter. 99.04% of the stock is owned by institutional investors.
Glaukos Stock Performance Shares of GKOS opened at $106.72 on Wednesday. The company has a market cap of $6.
04 billion, a PE ratio of -37.18 and a beta of 0.99.
The firm has a 50-day moving average of $133.61 and a 200-day moving average of $136.29.
Glaukos Co. has a one year low of $87.59 and a one year high of $163.
71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.
54 and a quick ratio of 4.71. Analysts Set New Price Targets Several research firms have recently issued reports on GKOS.
Wells Fargo & Company boosted their target price on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st.
Piper Sandler reiterated an “overweight” rating and set a $180.00 price objective (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th.
Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th.
UBS Group began coverage on shares of Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective on the stock.
Finally, Needham & Company LLC increased their price objective on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st.
One analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.25.
Get Our Latest Research Report on GKOS Insider Transactions at Glaukos In other news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.
24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18.
The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink .
6.40% of the stock is currently owned by corporate insiders. Glaukos Profile ( Free Report ) Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. Read More Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co.
( NYSE:GKOS – Free Report ). Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter .
.
